$GENI Cashflow Statement | Understand Stock

$GENI

$6.32 -$0.20 (3.07%) Close

$GENI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization
(Gain) loss on disposal of assets
(Gain) loss on fair value remeasurement of contingent consideration
Stock-based compensation
Change in fair value of derivative warrant liabilities
Non-cash consideration, net
Non-cash interest expense, net
Non-cash lease expense
Gain on lease termination
Loss on lease abandonment
Loss on lease abandonment and impairment
Amortization of contract costs
Deferred income taxes
Allowance for expected credit losses
Gain from equity method investment
Loss on abandonment of assets
(Gain) loss on foreign currency remeasurement

Changes in operating assets and liabilities
Effect of business combinations
Accounts receivable
Contract assets
Prepaid expenses
Other current assets
Other assets
Accounts payable
Accrued expenses
Deferred revenue
Other current liabilities
Operating lease liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Purchases of property and equipment
Capitalization of internally developed software costs
Contribution to equity method investments
Capitalization of installation costs
Distributions from equity method investments
Equity investments without readily determinable fair values
Repayment of executive loan notes
Purchases of intangible assets
Acquisition of business, net of cash acquired
Proceeds from disposal of assets
Net cash used in investing activities

Cash flows from financing activities:
dMY Technology Group, Inc. II transaction costs
Capitalization of Genius equity issuance costs
PIPE financing, net of equity issuance costs
Issuance of common stock in connection with additional equity offering, net of equity issuance costs
Issuance of B shares
Preference shares payout and Incentive Securities Catch-Up Payment
Proceeds from issuance of common shares, net of equity issuance costs
Repayment of loans and mortgage
Proceeds from exercise of Public Warrants
Repayment of promissory notes
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash
Net increase (decrease) in cash
Cash, beginning of period
Cash, end of period
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash activities:
Cash paid during the period for interest
Cash paid during the period for income taxes
Supplemental disclosure of noncash investing and financing activities:
Acquisition of common shares by subsidiary in connection with warrant redemptions
Promissory notes arising from equity method investments
Issuance of common stock in connection with business combinations
Preferred share accretion
Conversion of preference shares to common stock
Warrants acquired as part of merger with dMY Technology Group, Inc. II
Exercise of Private Placement Warrants

Comments